Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Acasti Pharma eyes phase III success with double data

<< Previous

Bullboard Posts

Next >>

Comment by Francine01on Jun 05, 2019 5:10pm

58 Views

Post# 29800984

RE:Acasti Pharma eyes phase III success with double data

 I had a lot of trouble listening to the video, since I was obsessed with Jan's haircut, which seems to have come straight from a 1980s movie, but I retained : non dillutive finaning after phase 3, partnerships and subvention (Minister Fitzbiggon is certainly Acasti friend). All good !!!

<< Previous

Bullboard Posts

Next >>

How a truck transportation and logistics company leverages acquisitions and technology